Effectiveness of the Moreau strain of Bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer.

被引：1
|
作者：
Chade, Daher Cezar
Machado, Andre
Waksman, Ricardo
Garcia, Guilherme
Esteves, Paulo
Adonias, Sanarelly
Botelho, Luis
Cordeiro, Mauricio
Murta, Claudio
Ribeiro-Filho, Leopoldo
Sarkis, Alvaro
Bastos, Diogo Assed
Dzik, Carlos
Srougi, Miguel
Nahas, William Carlos
机构：
[1] Univ Sao Paulo, Sao Paulo Canc Inst, Sao Paulo, Brazil
[2] Univ Sao Paulo, Sao Paulo, Brazil
[3] Univ Sao Paulo, Sao Paulo State Canc Inst, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4539
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guerin Downregulation of Nonmuscle-invasive Bladder Cancer
    Camargo, Juliana A.
    Passos, Gabriela R.
    Ferrari, Karen L.
    Billis, Athanase
    Saad, Mario J. A.
    Reis, Leonardo O.
    [J]. CLINICAL GENITOURINARY CANCER, 2018, 16 (03) : E587 - E593
  • [22] The impact on survival outcomes of different Bacillus Calmette-Guerin strains of nonmuscle invasive bladder cancer patients
    Liu, K.
    Zhao, H.
    Chen, X.
    Chiu, P. K.
    Ng, C.
    Teoh, J. Y.
    [J]. EUROPEAN UROLOGY, 2023, 83 : S396 - S396
  • [23] Effects of Bacillus Calmette-Guerin (BCG) and interferon α-2b on superficial bladder cancer.
    Zhang, Y
    Khoo, HE
    Gan, YH
    Mahendran, R
    Esuvaranathan, K
    [J]. CLINICAL CANCER RESEARCH, 1999, 5 : 3807S - 3807S
  • [24] Defining innate immune training potential as a predictor of Bacillus Calmette-Guerin immunotherapy response in nonmuscle-invasive bladder cancer.
    Jiang, Song
    Redelman-Sidi, Gil
    Pietzak, Eugene J.
    Bochner, Bernard H.
    Glickman, Michael S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [25] Cost-Effectiveness of Maintenance bacillus Calmette-Guerin for Intermediate and High Risk Nonmuscle Invasive Bladder Cancer EDITORIAL COMMENT
    Chang, Sam S.
    [J]. JOURNAL OF UROLOGY, 2020, 204 (03): : 449 - 449
  • [26] A phase I trial of chemoimmunotherapy combining bacillus Calmette-Guerin (BCG) and intravesical gemcitabine for patients with BCG-relapsing high-grade nonmuscle-invasive bladder cancer.
    Escano, De Jesus Manuel R.
    Sjoberg, Daniel D.
    McCarter, Melissa
    McGill, Marlena
    Goh, Alvin
    Donahue, Timothy F.
    Donat, Machele S.
    Cha, Eugene K.
    Herr, Harry W.
    Meraney, Anoop M.
    Al-Ahmadie, Hikmat A.
    Solit, David B.
    Dalbagni, Guido
    Bajorin, Dean F.
    Bochner, Bernard H.
    Pietzak, Eugene J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [27] BACILLUS CALMETTE-GUERIN (BCG) - MECHANISM OF ACTION IN SUPERFICIAL BLADDER-CANCER
    RATLIFF, TL
    [J]. UROLOGY, 1991, 37 (05) : 8 - 11
  • [28] Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Review of complications and their treatment
    Paterson, DL
    Patel, A
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1998, 68 (05): : 340 - 344
  • [29] The Challenge of Bacillus Calmette-Guerin Failure in Nonmuscle Invasive Bladder Cancer-What is the Next Step in Management?
    Lotan, Yair
    [J]. JOURNAL OF UROLOGY, 2013, 190 (03): : 832 - 833
  • [30] Bacillus Calmette-Guerin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?
    Tan, Wei Shen
    Grajales, Valentina
    Bree, Kelly
    Li, Roger
    Nogueras-Gonzalez, Graciela M.
    Navai, Neema
    Dinney, Colin
    Kamat, Ashish M.
    [J]. BJU INTERNATIONAL, 2023, 132 (04) : 384 - 386
12345